- Home
- LYB vs WAT Comparison
LYB vs WAT Comparison
Compare LYB & WAT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LYB
- WAT
- Stock Information
- Founded
- LYB 1955
- WAT 1958
- Country
- LYB United States
- WAT United States
- Employees
- LYB N/A
- WAT N/A
- Industry
- LYB Major Chemicals
- WAT Biotechnology: Laboratory Analytical Instruments
- Sector
- LYB Industrials
- WAT Industrials
- Exchange
- LYB Nasdaq
- WAT Nasdaq
- Market Cap
- LYB 20.3B
- WAT 17.0B
- IPO Year
- LYB N/A
- WAT 1995
- Fundamental
- Price
- LYB $53.38
- WAT $291.56
- Analyst Decision
- LYB Hold
- WAT Hold
- Analyst Count
- LYB 14
- WAT 14
- Target Price
- LYB $65.71
- WAT $374.07
- AVG Volume (30 Days)
- LYB 5.9M
- WAT 1.0M
- Earning Date
- LYB 08-01-2025
- WAT 08-04-2025
- Dividend Yield
- LYB 10.27%
- WAT N/A
- EPS Growth
- LYB N/A
- WAT 10.77
- EPS
- LYB 0.77
- WAT 11.09
- Revenue
- LYB $38,655,000,000.00
- WAT $3,046,056,000.00
- Revenue This Year
- LYB N/A
- WAT $6.27
- Revenue Next Year
- LYB $2.80
- WAT $6.49
- P/E Ratio
- LYB $115.30
- WAT $26.30
- Revenue Growth
- LYB 2.98
- WAT 5.89
- 52 Week Low
- LYB $47.55
- WAT $275.05
- 52 Week High
- LYB $99.36
- WAT $423.56
- Technical
- Relative Strength Index (RSI)
- LYB 43.64
- WAT 44.31
- Support Level
- LYB $47.55
- WAT $278.49
- Resistance Level
- LYB $52.88
- WAT $296.89
- Average True Range (ATR)
- LYB 2.41
- WAT 7.48
- MACD
- LYB -0.16
- WAT 2.68
- Stochastic Oscillator
- LYB 38.20
- WAT 53.76
About LYB LyondellBasell Industries NV (Netherlands)
LyondellBasell is a petrochemical producer with operations in the United States, Europe, and Asia. The company is the world's largest producer of polypropylene and also a major producer of polyethylene and propylene oxide. Its chemicals are used in various consumer and industrial end products. Well over half of LyondellBasell's production comes from its North American operations.
About WAT Waters Corporation
Water sells liquid chromatography, mass spectrometry, and thermal analysis tools. These analytical instruments provide essential information on various products, such as their molecular structures and physical properties, to help clients enhance the health and well-being of end users. As a percentage of sales in 2024, Waters generated 58% from biopharmaceutical customers, 31% from industrial clients, and 11% from academic/government institutions. In early 2026, Waters plans to merge with BD's life science and diagnostics business, which will substantially change those concentrations. Waters will wind up with more concentration in diagnostics (versus none now) and discovery-related life science tools.